Published in Antimicrob Agents Chemother on October 01, 1997
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob Agents Chemother (2000) 1.03
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis (2012) 0.98
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother (1998) 0.97
Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother (1999) 0.89
Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother (2004) 0.87
Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother (2004) 0.83
Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother (2001) 0.82
Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother (2000) 0.82
Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomedicine (2015) 0.80
Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrob Agents Chemother (2000) 0.79
The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol (1999) 0.75
Significance of algal polymer in designing amphotericin B nanoparticles. ScientificWorldJournal (2014) 0.75
Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine (2017) 0.75
Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. Clin Exp Immunol (1977) 3.19
Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A (1988) 2.22
Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst (1987) 1.95
Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet (1983) 1.88
Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet (1991) 1.87
Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis (1994) 1.79
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet (1992) 1.74
Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother (1992) 1.60
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol (1995) 1.42
The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol (1988) 1.33
Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother (1992) 1.18
Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol (1996) 1.16
Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg (1995) 1.09
Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis (1993) 1.05
Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg (1996) 1.04
Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis (1996) 1.03
Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol (1989) 1.03
Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg (1995) 0.86
Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus. Clin Infect Dis (1995) 0.86
Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis (1995) 0.85
Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf (1995) 0.80
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell (1996) 3.81
A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA (2000) 3.06
The germ theory, beriberi, and the deficiency theory of disease. Med Hist (1977) 2.80
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics (1997) 2.65
Molecular cloning and functional expression of a human cDNA encoding the antimutator enzyme 8-hydroxyguanine-DNA glycosylase. Proc Natl Acad Sci U S A (1997) 2.27
Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. Mol Cell Biol (1997) 1.85
U2 and U1 snRNA gene loci associate with coiled bodies. J Cell Biochem (1995) 1.70
Koch's postulates in relation to the work of Jacob Henle and Edwin Klebs. Med Hist (1985) 1.61
Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem (2000) 1.59
Probing functional organization within the nucleus: is genome structure integrated with RNA metabolism? Cold Spring Harb Symp Quant Biol (1993) 1.56
Genomic organization of the human PMS2 gene family. Genomics (1995) 1.50
Germ theory, hysteria, and Freud's early work in psychopathology. Med Hist (1980) 1.49
Ignaz Semmelweis, Carl Mayrhofer, and the rise of germ theory. Med Hist (1985) 1.47
Molecular cloning and functional analysis of a human cDNA encoding an Escherichia coli AlkB homolog, a protein involved in DNA alkylation damage repair. Nucleic Acids Res (1996) 1.41
SemmelWeis and his predecessors. Med Hist (1981) 1.40
Dynamic changes in the higher-level chromatin organization of specific sequences revealed by in situ hybridization to nuclear halos. J Cell Biol (1994) 1.37
A simple, rapid technique for precise mapping of multiple sequences in two colors using a single optical filter set. Genet Anal Tech Appl (1991) 1.34
The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol (1988) 1.33
Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol (2000) 1.32
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J (1999) 1.29
Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res (1997) 1.24
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol (2000) 1.22
Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood (1998) 1.21
Identification, chromosomal mapping and tissue-specific expression of hREV3 encoding a putative human DNA polymerase zeta. Carcinogenesis (1998) 1.17
The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol (1985) 1.15
Localizing DNA and RNA within nuclei and chromosomes by fluorescence in situ hybridization. Genet Anal Tech Appl (1991) 1.14
Reed-Sternberg cell genome expression supports a B-cell lineage. Blood (1999) 1.14
Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother (1983) 1.09
The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol (1989) 1.05
Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol Cell Endocrinol (2002) 1.04
Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol (1989) 1.03
Cloning and characterization of a novel human chemokine receptor. Biochem Biophys Res Commun (1998) 1.01
Production and actions of inhibin and activin during folliculogenesis in the rat. Mol Cell Endocrinol (2001) 1.00
Infantile hysteria and infantile sexuality in late nineteenth-century German-language medical literature. Med Hist (1983) 0.99
Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol (1988) 0.99
Cloning and functional analysis of the human IRF-3 promoter. DNA Cell Biol (1999) 0.98
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother (1998) 0.97
GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene (1997) 0.96
Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann Trop Med Parasitol (1992) 0.95
The development of Pasteur's concept of disease causation and the emergence of specific causes in nineteenth-century medicine. Bull Hist Med (1991) 0.94
Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations. Int J Immunopharmacol (1997) 0.92
Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J Drug Target (1995) 0.92
Ovarian estrogen receptor alpha and beta mRNA expression: impact of development and estrogen. Mol Cell Endocrinol (1999) 0.92
Induction of several acute-phase protein genes by heavy metals: a new class of metal-responsive genes. Biochemistry (1991) 0.91
Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene. DNA Cell Biol (1998) 0.90
Human geranylgeranyl diphosphate synthase: isolation of the cDNA, chromosomal mapping and tissue expression. J Lipid Res (1998) 0.90
Identification and characterization of a novel member of the fibroblast growth factor family. Eur J Neurosci (1998) 0.89
Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother (2003) 0.89
Josef Skoda's relation to the work of Ignaz Semmelweis. Medizinhist J (1984) 0.89
Cloning of a putative human neurotransmitter receptor expressed in skeletal muscle and brain. Biochem Biophys Res Commun (1998) 0.88
Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol (1998) 0.88
Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization. Genomics (1996) 0.87
Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol (1986) 0.87
The distribution of free and non-ionic vesicular sodium stibogluconate in the dog. J Drug Target (1993) 0.86
Isolation, characterization, and mapping of two human potassium channels. Biochem Biophys Res Commun (1997) 0.84
The effect of aging on constitutive mRNA levels and lipopolysaccharide inducibility of acute phase genes. Ann N Y Acad Sci (1991) 0.84
Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse. Exp Parasitol (1989) 0.84
Genomic organization, chromosomal mapping, and analysis of the 5' promoter region of the human MAdCAM-1 gene. Immunogenetics (1997) 0.84
Extending the capabilities of interphase chromatin mapping. Nat Genet (1992) 0.83
Investigating differential symptom profiles in major depressive episode with and without generalized anxiety disorder: true co-morbidity or symptom similarity? Psychol Med (2009) 0.81
Genetic control of drug-induced recovery from murine visceral leishmaniasis. J Pharm Pharmacol (1993) 0.79
Inhibition of mobility of Tetrahymena pyriformis by certain new local anaesthetics: an alternative in vitro approach to drug screening. Pharmazie (1993) 0.79
The Koch-Pasteur dispute on establishing the cause of anthrax. Bull Hist Med (1988) 0.79
The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. J Control Release (2012) 0.78
Giemsa banding and chiasma distribution in the desert locust. Heredity (Edinb) (1973) 0.78
Carrageenans and the proteolytic activity of human gastric secretion. J Pharm Pharmacol (1967) 0.78
Lyophilization of unit dose pharmaceutical dosage forms. Drug Dev Ind Pharm (2003) 0.77
Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin. Ann Trop Med Parasitol (1989) 0.76
Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. J Biomed Nanotechnol (2012) 0.76
Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J Parasitol (2010) 0.76
Activation of the fibrinolytic enzyme system in laboratory animals and in man. A comparative study. Thromb Diath Haemorrh (1971) 0.76
Cloning, mapping, and tissue distribution of a human homologue of the mouse jerky gene product. Biochem Biophys Res Commun (1997) 0.76
The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol (1999) 0.75
Nineteenth-century treatments for rabies as reported in the Lancet. Med Hist (1982) 0.75
Macroanionic inhibition of peptic activity by high and low molecular weight macroanions. Nature (1968) 0.75
Texts and documents. The earliest-known account of Semmelweis's initiation of disinfection at Vienna's Allgemeines Krankenhaus. Bull Hist Med (1991) 0.75
[Not Available]. Orvostort Kozl (1982) 0.75
Characteristics of clients receiving treatment in Australian drug and alcohol agencies: a national census. Drug Alcohol Rev (1992) 0.75
Drug delivery: lessons to be learnt from Leishmania studies. Nanomedicine (Lond) (2014) 0.75
Patch testing for nickel allergy. The influence of the vehicle on the response rate to topical nickel sulphate. Contact Dermatitis (1985) 0.75
Proceedings: Modification of trypsin activity by anti-inflammatory drugs. J Pharm Pharmacol (1974) 0.75
Edwin Klebs's Grundversuche. Bull Hist Med (2001) 0.75
Proceedings: Cationic inhibition of pepsin with polysines. J Pharm Pharmacol (1975) 0.75
Quantification of uptake of liposomal carboxyfluorescein by professional phagocytes in-vitro. A flow microfluorimetric study on the J774 murine macrophage cell line. J Pharm Pharmacol (1984) 0.75
Jacob Henle's views on disease causation. NTM (1993) 0.75
Skin reflectance measurements of patch test responses. Contact Dermatitis (1986) 0.75
Proceedings: Inhibition of tryptic activity by a gastric peptide. J Pharm Pharmacol (1975) 0.75
Peptic inhibition by macroanions. J Pharm Pharmacol (1968) 0.75
The effects of some synthetic compounds on in vitro fibrinolytic activity measured by different methods and the relevance to activity in vivo. Thromb Diath Haemorrh (1972) 0.75
Proceedings: Activation and inhibition of trypsin digestion of fibrin by sodium flufenamate. J Pharm Pharmacol (1973) 0.75
Causes of disease and death in the Babylonian Talmud. Medizinhist J (1991) 0.75